Kelly Jackson joined Fulcrum in 2016 with over 15 years of experience in biotech and pharmaceutical research, discovery and development. She was previously a director in R&D program leadership and business operations at Biogen. During her tenure, she provided strategic and operational guidance for the business process portfolio and was responsible for the prioritization and collaborative execution of initiatives driving efficiency, compliance and business agility. Kelly has also served as a member of the global clinical trial operations team at Merck, leading both international clinical development projects and transformation initiatives after joining the organization as a clinical research associate. Prior to transitioning to an industry role, she served as the director of research operations at the Mood Disorders Research Program at Case Western Reserve University/University Hospitals of Cleveland. In this role, she led the clinical research infrastructure including investigator-initiated, sponsor-driven, and NIH clinical research protocols. Kelly earned her bachelor’s degree in psychology & criminal justice from Mercyhurst University and a master’s degree in clinical counseling from John Carroll University.